Focused on anxiety, depression and dementia, we are advancing a pipeline of high potential therapeutics designed to meaningfully improve neuropsychiatric care.
Neuropsychiatric disorders present an overwhelming health and socioeconomic challenge affecting millions of people and their families across the United States.
17M+
adults experience at least one Major Depressive Disorder (MDD) episode 1
40M+
adults suffer from anxiety disorders, making these the most common neuropsychiatric disorders in the US 2
50%
of patients with MDD also have comorbid anxiety 1
6.5M+
adults are afflicted by neurodegenerative disorders: 5M+ Alzheimer’s Disease, 1M+ Parkinson’s Disease 3
$477B
spent annually related to people with anxiety, depression and dementia 4
~8M
adults experience Post-Traumatic Stress Disorder (PTSD) each year 2
Psy is addressing critical neuropsychiatric needs through innovation, proven expertise and deep commitment
Significantly improved therapies for CNS disorders are within reach. Powerful and proven advances in science and technology create compelling opportunities for success in a disease area demanding new approaches. Impactful enhancements in drug discovery include greater understanding of disease biology, breakthroughs in chemistry and data-driven decision-making.
Psy’s team of leading neuropsychiatric experts combine these advances with our integrated translational approach throughout the drug discovery and development process. Pioneering, flexible and highly productive, Psy is strongly positioned to be a leader in this emerging and exciting new era of life-changing treatments for people with neuropsychiatric disorders.
Meet Our Team
Our mission-driven team includes leading scientists, clinicians and business-building executives dedicated to delivering impactful therapies for people with CNS disorders.
Check Out Our Pipeline
Our risk-balanced pipeline consists of eight compelling drug programs primarily focused on anxiety, depression and dementia.
Explore Our Approach
We combine our deep expertise in neuropsychiatric drug development with innovative technologies to create significant value for those we serve.
1 Sources: NIMH
2 Sources: Anxiety and Depression Association of America (ADAA)
3 Sources: Parkinson’s Foundation, Alzheimer’s Association
4 Sources: Alzheimer’s Association, ADAA, NIH/WHO